Over at In the Pipeline, Derek Lowe blogs about the outcome of all those compounds that are discovered but can't be used as therapeutics. After looking at a particular compound that will never be used as a therapeutic, he writes, "But all this brings up another thing that we were talking about around here -- how much do drug companies owe academia for working out fundamental biochemistry and molecular biology?